0001493152-26-013646
SEC filingInterpace Biosciences reported $38.7M revenue with resilient 62.3% gross margins and $4.1M operating income, culminating in $24.6M net income driven by deferred tax asset realization that boosted diluted EPS to $0.89.
Interpace Biosciences, Inc. (IDXG) delivered FY2025 results shaped by reimbursement challenges and tax dynamics. Revenue stood at $38.7 million, with the primary driver being the loss of PancraGEN reimbursement in April 2025, leading the Company to cease accepting specimens after May 2, 2025. This topline pressure explains the revenue outcome while highlighting vulnerability to payer decisions in genomic testing.
Net income surged to $24.6 million, or $0.89 diluted EPS, propelled by partial deferred tax asset release following the annual analysis of expected future income realizability. This non-cash benefit reflects enacted tax laws applied to temporary differences between tax and book bases, providing a one-time lift without altering core operations.
Looking forward, Interpace continues commercializing tests for personalized cancer medicine. Potential supply issues with new test ramps and competition in clinical services remain risks, as noted in business disclosures. The deferred tax methodology ensures prudent recognition of future tax consequences, aligning with ongoing realizability assessments.